Skip to content
    ACTG
    Earnings call· Jun 2026(Q2 FY26)

    ACACIA RESEARCH Q2 FY26 earnings call ACTG

    Aug 5, 2026 Source

    Executive summary

    Acacia Research Corporation Q2 FY26 — Strong Operating Performance and IP Licensing

    Acacia Research delivered a strong second quarter, driven by robust performance across its operating businesses and significant licensing revenue from its Intellectual Property platform. The company continues to prioritize long-term intrinsic value creation through disciplined capital allocation and active ownership, leveraging its strong balance sheet to pursue attractive acquisition opportunities amidst market dislocation. While facing some segment-specific headwinds and a legacy investment write-down, management remains focused on operational efficiency and strategic growth.

    Highlights

    5

    • Total revenue reached $114.6 million, significantly up from $51.2 million in the prior year.

    • Operated segment adjusted EBITDA was $22.8 million, demonstrating strong underlying business performance.

    • Intellectual Property segment generated $60.6 million in licensing revenue, driven by a significant Wi-Fi 6 settlement.

    • Ended the quarter with $334.6 million in cash, securities, and loans receivable, maintaining no parent company debt.

    • Public securities portfolio contributed $9.4 million in gains, demonstrating effective capital deployment.

    Concerns

    4

    • Consolidated G&A expense totaled $19.6 million, including $3.7 million of nonrecurring legacy litigation expense in the IP segment.

    • Deflecto's adjusted EBITDA was $1.1 million, reflecting softer end markets despite operational improvements.

    • Full write-down of the MalinJ1 investment due to liquidity issues at Mycovia Pharmaceuticals, impacting book value.

    • GAAP net income attributable to Acacia Research Corporation was only $47,000 or $0.00 per diluted share.

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Benchmark (Energy Operations)
    Delivered another record revenue quarter with operating performance and cash flow exceeding expectations. Production from the Cherokee development performed in line with expectations.
    Free cash flow: $6.5 million
    		$20.5 million——Adjusted EBITDA: $9.8 million
    Deflecto (Manufacturing Operations)
    Continued progress with manufacturing optimization, organizational streamlining, cost management, and pricing initiatives. Well positioned for meaningful operating leverage as demand improves.
    		$27.1 million——Adjusted EBITDA: $1.1 million
    Printronix (Industrial Operations)
    Generated consistent cash flow and improved profitability through disciplined operational execution, leveraging installed base and global distribution network for higher-margin consumables.
    Free cash flow: $900,000
    		$6 million——Adjusted EBITDA: $1 million
    Intellectual Property
    Produced strong results driven primarily by a significant licensing settlement within the Wi-Fi 6 portfolio. Cost structure significantly rationalized.
    		$60.6 million——Adjusted EBITDA: $10.9 million

    Operational metrics

    12
    Total company adjusted EBITDA
    $17.3
    Q2 FY26

    Total company adjusted EBITDA was $17.3 million.

    Operated segment adjusted EBITDA
    $22.8
    Q2 FY26

    Operated segment adjusted EBITDA of $22.8 million.

    Cash, securities and loans receivable
    $334.6increased by $4.7M QoQ
    Q2 FY26

    Ended the quarter with $334.6 million of cash, securities and loans receivable, an increase of approximately $4.7 million during the quarter.

    Parent company debt
    $0
    Q2 FY26

    Continuing to maintain no parent company debt.

    Adjusted net income attributable to Acacia Research Corporation
    $12.8
    Q2 FY26

    Adjusted net income attributable to Acacia Research Corporation was $12.8 million or $0.13 per diluted share.

    Book value per share
    $5.71vs $5.87 prior quarter end
    Q2 FY26

    Book value at quarter end was $557 million or $5.71 per common share compared to $567.2 million or $5.87 per share at prior quarter end.

    Book value increase from operating segments
    $15.9
    Q2 FY26

    Increases to book value were primarily driven by $15.9 million in operating income from our operating segments.

    Book value increase from public equity portfolio
    $9.4
    Q2 FY26

    Increases to book value were primarily driven by $15.9 million in operating income from our operating segments and $9.4 million in gains from our public equity portfolio.

    Nonrecourse debt
    $59.5
    Q2 FY26

    Consisting of $59.5 million of nonrecourse debt at Benchmark.

    Nonrecourse debt
    $30.9
    Q2 FY26

    And $30.9 million of nonrecourse debt at Deflecto.

    Nonrecurring legacy litigation expense
    $3.7
    Q2 FY26

    Second quarter results also included approximately $3.7 million of nonrecurring expense associated with the legacy litigation matter that we believe is substantially complete and not representative of the platform's ongoing cost structure.

    MalinJ1 investment write-down
    full write-down
    Q2 FY26

    During the second quarter, we recorded a full write-down following developments impacting Mycovia Pharmaceuticals, the underlying biotechnology company.

    Industry KPIs

    1
    MetricValueDetails
    Capital returns—

    Deals & partnerships

    1
    Mycovia PharmaceuticalsPotential financing alternative and direct ownership interest

    Acacia is actively working with Mycovia to evaluate potential financing alternatives that would allow it to fund operations through upcoming FDA milestones. One potential transaction would give Acacia a direct ownership interest in Mycovia, rather than an indirect economic interest through milestone and royalty rights.

    Risks & headwinds

    5
    Episodic nature of licensing activityOngoing

    Licensing revenue of $60.6 million in Q2 FY26, but quarterly results can vary significantly.

    Mitigation: Aggressively managing the platform from a cost perspective; significantly reduced operating expenses; amortization of legacy intangible assets declining.

    Legacy litigation expenseQ2 FY26

    $3.7 million nonrecurring expense in Q2 FY26

    Mitigation: Believed to be substantially complete and not representative of ongoing cost structure; optimistic about potential recovery exceeding associated cost.

    Liquidity issues and contraindication for VIVJOAOngoing

    Full write-down of MalinJ1 investment in Q2 FY26

    Mitigation: Actively working with Mycovia to evaluate potential financing alternatives; exploring direct ownership interest to participate in value creation.

    Biotechnology investment inherent riskOngoing

    No assurance that a transaction will be completed or that Mycovia will achieve its regulatory objectives.

    Mitigation: Acacia is not a traditional biotech investor but uniquely positioned to execute in such situations; managing actively and with discipline.

    Softer end markets for DeflectoCurrent

    Adjusted EBITDA of $1.1 million in Q2 FY26

    Mitigation: Manufacturing optimization, organizational streamlining, disciplined cost management, and pricing initiatives; well positioned for operating leverage as demand improves.

    What to watch in Q3 FY26

    4

    Deflecto operating leverage

    Next quarter / future quarters
    CurrentAdjusted EBITDA of $1.1 million in Q2 FY26
    TargetMeaningful operating leverage as demand improves

    Why it matters

    Indicates whether Deflecto's restructuring efforts are translating into improved profitability as market conditions normalize.

    As demand improves, we believe Deflecto is well positioned to benefit from meaningful operating leverage going forward⏳.

    Q&A highlights

    4

    Inquired if Q2 Benchmark FCF and EBITDA included a full quarter from the wholly-owned well, and about plans for additional wells and their expected performance.

    Management confirmed the Q2 results included a full quarter from the Cherokee well, which started producing early in Q2. They have several units identified for drilling, aiming for one producing well and one PUD per unit. Future wells are underwritten to perform similarly to the Cherokee well.

    “we're underwriting to type curves in future wells that look similar to the performance of the Cherokee well that we drilled in Q1.”

    asked by Brett Reiss · answered by Martin McNulty

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Approach and Capital Allocation

    Acacia emphasizes compounding long-term intrinsic value per share through disciplined capital allocation, acquiring businesses at attractive valuations, improving operations, and deploying capital for attractive long-term returns. The company remains patient and disciplined in pursuing acquisition opportunities, focusing on situations where operational expertise can create value beyond the purchase price, particularly in acute situations outside broad auction processes.

    02

    Intellectual Property Platform Performance

    The IP platform generated significant licensing revenue of $60.6 million, primarily from a Wi-Fi 6 portfolio settlement. Management views this as a differentiated, noncorrelated asset class. The platform's cost structure has been significantly rationalized, and amortization of legacy intangible assets is declining. The company incurred $3.7 million in nonrecurring legal expenses for a legacy litigation matter, which is not expected to be an ongoing cost.

    03

    Life Sciences Portfolio Developments

    AMO Pharma, in which Acacia is the second-largest shareholder, received constructive regulatory advice from the FDA, MHRA, and Health Canada for its AM02 therapeutic candidate, supporting the design of a planned registrational clinical study. Separately, Acacia recorded a full write-down of its MalinJ1 investment due to liquidity issues at Mycovia Pharmaceuticals, which holds the FDA-approved antifungal drug VIVJOA. Acacia is actively exploring financing alternatives for Mycovia, potentially converting its indirect interest into a direct ownership stake.

    04

    Public Securities Investment Strategy

    Acacia actively invests in small-cap public markets, seeking compelling opportunities where market prices diverge from underlying value. This strategy can involve establishing toehold positions for potential broader strategic transactions or monetizing investments when risk-reward becomes compelling. The company successfully exited one such investment during the quarter, realizing an attractive return.

    05

    Benchmark Operating Business

    Benchmark delivered record revenue of $20.5 million, adjusted EBITDA of $9.8 million, and free cash flow of $6.5 million. The company's recently developed drilling inventory continues to show attractive economics, and management is evaluating additional drilling opportunities using a disciplined underwriting framework. Commodity hedging is used to reduce earnings volatility and protect downside risk, not to speculate on prices.

    06

    Deflecto and Printronix Operations

    Deflecto generated $27.1 million in revenue and $1.1 million in adjusted EBITDA, continuing manufacturing optimization and restructuring initiatives to position for profitable growth and operating leverage as demand improves. Printronix generated $6 million in revenue, $1 million in adjusted EBITDA, and $900,000 in free cash flow, demonstrating resiliency through strong cash generation, improved product mix, and disciplined cost management in a mature market.

    AI-generated summary of the company’s earnings call. Not investment advice.